GSK

37.94
0.35 (0.93%)
At close: Mar 03, 2025, 3:59 PM
37.92
-0.05%
After-hours: Mar 03, 2025, 05:09 PM EST

Company Description

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.

It operates through two segments, Commercial Operations and Total R&D.

The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines.

It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.

It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines.

The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022.

GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.

GSK
GSK logo
Country UK
IPO Date Mar 28, 1980
Industry Drug Manufacturers - General
Sector Healthcare
Employees 68,629
CEO Emma Natasha Walmsley

Contact Details

Address:
980 Great West Road
Brentford,
UK
Website https://www.gsk.com

Stock Details

Ticker Symbol GSK
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001131399
CUSIP Number 37733W204
ISIN Number US37733W2044
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Emma Natasha Walmsley Chief Executive Officer & Director
Sally Jackson Senior Vice President of Global Communications & Chief Executive Officer Office
Diana Conrad Chief People Officer
Julie Belita Brown A.C.A. Chief Financial Officer & Executive Director
David Simon Redfern BSc (Hons), CA President of Corporate Development
James Ford Senior Vice President & Group General Counsel of Legal & Compliance
Nick Stone SVice President & Head of Investor Relations
Philip C. Thomson President of Global Affairs
Shobie Ramakrishnan Chief Digital & Technology Officer
Tony Wood Chief Scientific Officer and Head of R&D

Latest SEC Filings

Date Type Title
Feb 28, 2025 6-K Filing
Feb 27, 2025 6-K Filing
Feb 27, 2025 6-K Filing
Feb 26, 2025 6-K Filing
Feb 26, 2025 6-K Filing
Feb 25, 2025 6-K Filing
Feb 24, 2025 6-K Filing
Feb 24, 2025 6-K Filing
Feb 21, 2025 6-K Filing
Feb 21, 2025 6-K Filing